Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
A phase 2 trial of Zongertinib, Cisplatin, Carboplatin, Pemetrexed and Pembrolizumab in non-small-cell lung cancer, run by Boehringer Ingelheim, now recruiting.
Overview
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab is a phase 2 interventional study registered as NCT07486817 by Boehringer Ingelheim, with 60 participants planned, started 2026-06-04 and due to reach its primary completion in 2027-08-12. Interventions recorded: Zongertinib, Cisplatin, Carboplatin, Pemetrexed and Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Shares Zongertinib, Boehringer Ingelheim, Pemetrexed, Cisplatin and the tag pipeline.
- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialBeamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Shares Zongertinib, Boehringer Ingelheim and the tag pipeline.
- TrialA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.